Could a single pill crack the code of treating Alzheimer’s disease?alzheon2025-01-04T15:43:38-05:00January 2nd, 2025|
Alzheon nabs $100M in series E to advance oral Alzheimer’s drugalzheon2024-06-26T15:07:42-04:00June 24th, 2024|
Alzheimer’s Drug Developer Alzheon Closes $100M Series E Financingalzheon2024-06-14T12:13:01-04:00June 12th, 2024|
With fresh $100M, Alzheon lays out strategy for Alzheimer’s approval next yearalzheon2024-06-14T12:25:50-04:00June 12th, 2024|
Breakthroughs in Alzheimer Research Pave Way for New Era of Treatment: Martin Tolar, MD, PhDalzheon2024-06-26T14:05:46-04:00June 11th, 2024|
Beginning a New Era of Precision Alzheimer’s Therapeuticsalzheon2024-06-03T14:44:54-04:00April 2nd, 2024|
Newsweek Investment Report: Interview with Dr. Martin Tolar, President & CEO of Alzheon, Inc. January 2024alzheon2024-06-03T14:42:41-04:00January 11th, 2024|
ALZ-801 for 2 years seen to sustain cognition in early Alzheimer’salzheon2023-10-02T11:49:22-04:00September 22nd, 2023|
